Ozempic Brings Again the ‘Mac vs PC’ Advertisements for the GLP-1 Period

Novo Nordisk’s Ozempic kicked off the GLP-1 craze when it launched in 2018 for the remedy of Sort 2 diabetes. For years, the Danish pharma big held onto its crown because the dominant participant within the GLP-1 drug market. However a chronic scarcity and growing competitors have made 2025 a a lot rougher yr for the corporate.

Now, Novo Nordisk is rolling out an advert marketing campaign that reunites actors Justin Lengthy and John Hodgman, because it appears to increase the marketplace for its blockbuster diabetes drug forward of patent expirations around the globe.

The marketing campaign riffs on Apple’s iconic mid-2000s adverts, which featured Lengthy and Hodgman as anthropomorphic versions of a laid-back Mac and a stuffy PC, respectively.

This time round, Lengthy performs Ozempic, whereas Hodgman takes on the position of rival GLP-1 diabetes medicine. The adverts take a really completely different strategy from the normal Large Pharma commercials viewers are used to seeing.

Within the first spot, the 2 face off in a trivia recreation that informs viewers that Ozempic is the one GLP-1 drug for diabetes that has been authorised by the Meals and Drug Administration (FDA) to reduce the risk of worsening chronic kidney disease. Lengthy ends the industrial by calmly studying by way of the drug’s intensive security info.

Viewers will begin seeing the adverts as we speak throughout digital channels, together with social media and video streaming providers.

Ozempic is a once-weekly injectable treatment used to assist regulate blood sugar ranges in folks with Sort 2 diabetes. After its launch, the drug additionally turned extensively identified for its weight-loss results, which led Novo Nordisk to introduce Wegovy, a separate model authorised particularly for weight reduction.

It’s value noting that the brand new marketing campaign is explicitly targeted on Ozempic, not Wegovy.

The booming reputation of Ozempic and Wegovy helped flip Novo Nordisk into the 12th most valuable company on the planet by market capitalization in March 2024. However a scarcity, which opened the door to cheaper, off-brand alternate options, together with rising competitors from Eli Lilly, maker of the rival diabetes drug Mounjaro, despatched Novo Nordisk shares sliding final yr.

Amid the downturn, longtime CEO Lars Fruergaard Jørgensen introduced in Could that he can be leaving the company. At the moment, Novo Nordisk has slipped to roughly fifty fifth place globally by market cap, whereas Eli Lilly stays near the top at 13th.

The brand new advert marketing campaign is geared toward increasing the marketplace for Ozempic as key patents start to run out, ushering in much more competitors. Whereas the core U.S. patent for semaglutide, the lively ingredient behind Ozempic, does not expire until the next decade, patent protections in China and Canada are already lapsing this yr.

“As a result of in a variety of markets we have now misplaced exclusivity this yr, we’ll get competitors. And when you have got a really excessive market share, competitors will take a few of that share away. We have to focus in the marketplace growth,” Novo Nordisk CEO Maziar Mike Doustdar stated on the JP Morgan Healthcare Convention final week, The Wall Street Journal reported.

Novo Nordisk is betting that growth can come from emphasizing Ozempic’s different FDA-approved makes use of, together with its cardiovascular health benefits.

Nevertheless it stays to be seen whether or not this type of marketing campaign can actually transfer the needle but in a market the place sufferers usually don’t have a lot say in any respect, and find yourself taking whichever medicine their physician prescribes and their insurance coverage is keen to pay for.